Tag: depression

  • Electroconvulsive Therapy found to be safe and effective treatment for some mental illnesses

    Electroconvulsive Therapy found to be safe and effective treatment for some mental illnesses

    [ad_1]

    Researchers have found that Electroconvulsive Therapy (ECT), where an electric current is passed through the brain, can reduce the severity of mental illnesses.

    ECT is a safe and effective treatment for some mental illnesses including severe/psychotic depression, postnatal psychosis and mania. Patients are placed under general anaesthetic and the brain is stimulated with short electric pulses. This causes a brief seizure which lasts for less than two minutes.

    The use of ECT across Scotland was assessed over an 11-year period from 2009 to 2019 using data from the Scottish Electroconvulsive Therapy (ECT) Audit Network (SEAN). The Scotland-wide naturalistic study assessed the efficacy and side effects of ECT across a range of common mental illnesses such as depression, bipolar depression, schizophrenia, and mania.

    Key findings from the study include:

    • ECT was shown to be effective in reducing illness severity, as measured by Clinical Global Impression Scale (CGI-S). CGI-S is a validated clinician administered assessment tool which measures illness severity.
    • 2,920 ECT episodes had CGI-S scores recorded for patients before and after treatment. The mean CGI-S score prior to treatment indicated marked illness severity (5.03 95% CI 4.99-5.07), whilst after treatment, the mean CGI-S score was reduced to 2.07, (95% CI 2.03-2.11) indicating a reduction to borderline illness severity.
    • The study also assessed side effects of ECT. Anaesthetic complications and prolonged seizures were rare, occurring in <1% of treatment episodes. Cardiovascular complications were reported in 2.2%. Nausea was reported in 7.2% and muscle aches in 12%. Confusion was reported in 19% and cognitive side effects in 26.2%.

    Dr Julie Langan Martin, Senior Clinical Lecturer in Psychiatry, Director of Education at the University of Glasgow, Scotland, said “Our findings from this large naturalistic study across Scotland from over an 11-year period reinforce the widely held, but nonetheless underexplored view, that ECT is both a safe and effective treatment when delivered to appropriate groups of people with severe mental illness. Monitoring of side effects, especially cognitive side effects should be undertaken carefully and rigorously in all patients receiving ECT.”

    This study on ECT presents compelling evidence of its effectiveness in reducing the severity of mental illnesses, with major side effects found to be rare. It challenges common misconceptions and stigmas associated with ECT, providing valuable insights that can reshape public perceptions and stimulate informed discussions among healthcare professionals.”

    Dr Julian Beezhold, Secretary General of the European Psychiatric Association

    The European Congress of Psychiatry takes place from 6-9 April 2024 in Budapest, Hungary, and represents Europe’s largest congress dedicated to psychiatry, with over 4000 participants: epa-congress.org.

    [ad_2]

    Source link

  • Gut-friendly psychobiotics could brighten moods and fight depression

    Gut-friendly psychobiotics could brighten moods and fight depression

    [ad_1]

    In a recent review published in the journal Nutrients, researchers investigated the psychobiotic treatment of depression by restoring microbial balance and regulating the microbiome-gut-brain (MGB) axis.

    Depression is a global health concern that causes pain, lost productivity, higher healthcare expenditures, and a high risk of suicide. Dysbiosis, a disruption in gut microbiome homeostasis, can affect the gut-brain axis (GBA), resulting in microbial alterations. Psychobiotics, which have favorable effects on the gut barrier, immunological responses, cortisol expression, and the hypothalamic-pituitary-adrenal (HPA) axis, might be used as a supportive treatment for depression, particularly in treatment-recalcitrant depression (TRD) cases.

    The Power of Psychobiotics in Depression: A Modern Approach through the Microbiota–Gut–Brain Axis: A literature Review. Image Credit: T. L. Furrer / ShutterstockThe Power of Psychobiotics in Depression: A Modern Approach through the Microbiota–Gut–Brain Axis: A literature Review. Image Credit: T. L. Furrer / Shutterstock

    About the review

    In the present review, researchers presented clinical evidence and elucidated the underlying mechanisms of psychobiotic therapies for depression via their effects on gut-brain communication.

    Association between the gut-brain axis and depressive disorders

    Depression is a complex biological disorder influenced by a variety of molecular mechanisms, such as neurotransmitter reduction, a decrease in brain-derived neurotrophic factor (BDNF), an abnormally stressed HPA axis, an increase in pro-inflammatory gut microbial responses, and vagus nerve interaction between gut microbiota and brain. The GBA and intestinal microbes are inextricably linked, with MGB influencing neurobehavioral outcomes via endocrine, neuronal, and immunological mechanisms. Dysbiosis, or a disruption in the GBA axis, can alter the intestinal microbiome, influencing neuronal function, immunology, and gut inflammation.

    Chronic stress impairs intestinal homeostasis and changes gut microbial composition, increasing Faecalibaculum and Clostridium in individuals while decreasing Lactobacillus and Bifidobacterium. Recent animal models have demonstrated a relationship between the gut-brain axis and stress sensitivity and resilience. The intestinal microbiome influences inflammatory responses and brain states and is associated with psychiatric conditions such as major depressive disorder, bipolar disorder, psychosis, schizophrenia, anorexia nervosa, anxiety disorders, obsessive-compulsive disorder, post-traumatic stress disorder, and attention-deficit hyperactivity disorder (ADHD).

    Graphical Abstract

    Graphical Abstract

    Gut microbial metabolites involved in antidepressant actions

    The gut microbiome is a vital metabolite source, facilitating communications between the gut and the central nervous system. These metabolites consist of tryptophan, gamma-aminobutyric acid (GABA), serotonin, histamine, 5-hydroxytryptamine (5-HT), short-chain fatty acids (SCFAs), acetylcholine, and dopamine (DA). Microbial metabolites impact various mechanisms important for mental health, such as immunological and neuroendocrine system development, nutrition metabolism modulation, and xenobiotic transformation. They also help to maintain gut barrier function, strengthen the intestinal mucosa, and keep dangerous infections and poisons out of circulation. SCFAs are necessary for emotional states and cognition, impacting the host’s brain via G-protein-coupled receptors. They supply energy to colonocytes, protect the intestinal barrier, regulate inflammatory responses, and regulate hunger hormones. Increased SCFAs can reduce neuroinflammation and boost BDNF synthesis, boosting brain neuroplasticity.

    Impact of probiotic gut microbes on depression

    Psychobiotics are probiotic bacteria that boost mental health by improving the intestinal barrier and modifying the immune response in the gut-associated lymphoid tissue (GALT), which plays a role in inflammation development. The gut microbiota is crucial in the pathophysiology of depression since it regulates inflammatory processes. Bifidobacterium breve boosts BDNF levels, lowers interleukin-6 (IL-60) and TNF-alpha (TNF-α) levels, and enhances cognitive function.

    Lactic acid bacteria (LAB) reduce neuroinflammation, lower kynurenine levels, and promote tight junction (TJ) expression. Lactobacillus plantarum 299v boosts dopamine levels and helps with selective serotonin reuptake inhibitor (SSRI) therapy, resulting in better cognitive performance and lower kynurenine levels. Akkermansia muciniphila suppresses inflammatory cytokines in microglial cells, which lowers depressive-like behavior. Clostridium butyricum protects against neurological dysfunction, whereas Faecalibacterium prausnitzii lowers corticosterone and C-reactive protein (CRP) levels while boosting IL-10 levels and lowering cognitive impairment in Alzheimer’s disease rats.

    Clinical evidence highlighting the psychobiotic features of bacterial strains

    Postbiotics such as Bacillus coagulans MTCC 5856 and Bifidobacterium longum 1714 can help with irritable bowel syndrome (IBS) symptoms and depression. Probiotics such as Bifidobacterium longum 1714 and NCC3001 help to decrease stress and enhance memory. When coupled with antidepressants, these probiotics can effectively cure TRD. Probiotics such as Lactobacillus casei Shirota and Lactobacillus gasseri CP2305, at 2.5 × 109 CFU/g, enhance general health and lower mood disorders. Multi-strain probiotic medication also boosts general health, alleviates anxiety symptoms, and reduces inflammation. Lactobacillus gasseri fermented black soybean beverage helps healthy individuals sleep better and feel less stressed. Probiotic milk drinks and fermented soybean seed paste improve cognitive performance in individuals with moderate cognitive impairment and Alzheimer’s disease.

    The review highlights probiotics’ involvement in lowering depressive symptoms and their importance in mental health. The gut microbiota is crucial for digestion, food absorption, and psychiatric concerns such as stress reduction and anxiety. With a shift in the emphasis in modern life from infectious disorders to more common mental illnesses such as depression, good dietary habits and optimal intestinal function are critical for mental well-being, with probiotics playing an important role.

    Journal reference:

    • Dziedzic, A.; Maciak, K.; Bliźniewska-Kowalska, K.; Gałecka, M.; Kobierecka, W.; Saluk, J. The Power of Psychobiotics in Depression: A Modern Approach through the Microbiota–Gut–Brain Axis: A literature Review. Nutrients 2024, 16, 1054. DOI: 10.3390/nu16071054, https://www.mdpi.com/2072-6643/16/7/1054

    [ad_2]

    Source link

  • Exploring prebiotics and probiotics as dual fighters against depression and obesity

    Exploring prebiotics and probiotics as dual fighters against depression and obesity

    [ad_1]

    Depression is among the most prevalent and potentially serious mental health disorders, accounting for up to 800,000 suicides a year. The risk factors for depression have, therefore, undergone much exploration.

    A recent study published online in Nutrients deals with the interactions between depression and nutrition, coupled with exercise.

    Study: The Role of Gut Microbiota, Nutrition, and Physical Activity in Depression and Obesity—Interdependent Mechanisms/Co-Occurrence. Image Credit: Bits And Splits/Shutterstock.comStudy: The Role of Gut Microbiota, Nutrition, and Physical Activity in Depression and Obesity—Interdependent Mechanisms/Co-Occurrence. Image Credit: Bits And Splits/Shutterstock.com

    About depression

    Depressive disorders include several categories, including persistent depressive disorder (dysthymia), premenstrual dysphoric disorder, as well as depression induced by addictive drugs or medications or by medical conditions.

    All are characterized by sadness and irritability, with bodily and mental changes. The effect is a lowered quality of life and impaired functioning.

    Moreover, depression is known to increase the risk for a number of metabolic diseases, such as diabetes, obesity, and ischemic heart disease.

    Conversely, dietary patterns are linked to mental health as well as malnutrition. For instance, excessive fat intake leads to chronic inflammation and obesity.

    Obesity

    Obesity is defined as the accumulation of body fat in excess, as measured by the body mass index (BMI) and the body fat percentage. It is associated with a higher risk of cardiovascular disease (CVD), insulin resistance, cancer, and nerve damage.

    Risk factors for obesity are well-known and include gender, age, smoking, apart from the consumption of excessive fat and of processed foods, which are typical of Western diets.

    Obesity and depression often affect the same individual, along with anxiety disorders. They have a common mechanism of action, as seen by their bidirectional association.

    People who are depressed often indulge in comfort eating, which may increase body weight, especially if the person is also inactive. The risk of obesity in people undergoing emotional stress is almost 40% higher.

    Similarly, obese people are almost 20% more likely to become anxious or depressed because of negative self-image as well as adverse social perceptions that they are too lazy or undisciplined to regulate their diet and their weight. The treatment of depression with antidepressants is effective but may cause weight increase.

    Unfortunately, both obesity and depression are among the most prevalent disorders globally and have a high death rate, leading to powerful scientific interest in their interrelationships.

    Gut microbiota

    The gut microbiota is essential to proper energy storage and metabolism, but shows marked variability in obese vs lean individuals. This includes lower diversity and fewer commensal bacteria but more pathogenic microbes in the obese. The resulting aberration in metabolism may contribute to obesity.

    The need for a rational diet along with therapies like psychotherapy and medication to treat patients with depression is stressed by some scientists.

    In addition, probiotics and prebiotics may be required, along with nutritional supplements, to correct dysbiosis and vitamin deficiencies.

    Probiotics and gut microbiota

    The researchers sought to understand how gut microbes may be useful in treating both obesity and depression and the role of probiotics and prebiotics in such therapy.

    The review suggests that about 57% of the composition of the gut microbiota responds to dietary patterns.

    Probiotics strengthen the gut barrier and modulate the immune system. Their use is associated with improving depressive symptoms, perhaps by supplying vitamin D and short-chain fatty acids (SCFAs), which combat inflammation.

    Some strains of probiotic bacteria directly affect neural pathways. They inhibit the depression-inducing hypothalamic–pituitary–adrenal axis (HPA axis), and promote the secretion of the anti-stress neurotransmitter GABA, also known as gamma-aminobutyric acid.

    Others produce gut neurotransmitters that also affect the brain, affecting the mood for the better.

    Some clinical trials in humans suggest a positive effect of probiotics on depressive disorders as well as on obesity and related metabolic conditions like insulin resistance, type 2 diabetes, and nonalcoholic fatty liver disease (NAFLD).

    Further research is essential to validate these results, especially as probiotics work well on gut health and overall disease control only as part of a holistic management strategy, including proper diet, exercise, stress regulation, and adequate sleep.

    Bacterial strains linked to improved neural pathways, sometimes called psychobiotics, include multiple Lactobacillus strains like Lactobacillus casei Shirota, Lactobacillus fermentum NS8 and NS9, and Lactobacillus rhamnosus JB-1, as well as Bifidobacterium strains like Bifidobacterium longum Rosell-175, Bifidobacterium longum 1714, and Bifidobacterium longum NCC3001.

    Diet and mental health

    The brain receives a good share of absorbed nutrients and utilizes them to keep itself healthy. For instance, regeneration, neuroplasticity, and an adequate antioxidant reserve depend on the proper supply of nutrients to the brain.

    Supplementation with fatty acids like eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), magnesium, folate, and vitamins E and D have been suggested to be beneficial in countering or mitigating severe depression and reducing neuroinflammation.

    Specific diets like the Mediterranean diet (MD), the DASH (Dietary Approaches to Stop Hypertension), or vegetarian diets have frequently been assessed for their relationship with physical and mental health.

    The authors of the current study found reduced depression and obesity risk with both the DASH and the MD, but contradictory data with vegetarian and vegan diets. However, high-quality vegetarian diets were protective against depression, underlining the pivotal role of diet quality in the type of diet chosen.

    Physical activity and obesity/mood disorders

    There is ample evidence that weight management is aided by increasing the overall energy expenditure and improving the mood, with reduced anxiety and depression. Aerobic exercise has been recommended for its ability to build fitness and help reduce weight.

    Physical exercise is linked with lengthening telomeres, a metabolic health biomarker. It is also associated with better brain health, sleep quality, and reduced depressive symptoms.

    Physical exercise is also linked to better gut microbiota composition, stronger commensals, and more anti-inflammatory bacteria.

    Early-life exercise may promote the development of bacteria that can help the host adapt to changing conditions and promote healthy brain development.

    The broader impact of obesity and depression

    Depression is associated with increased mortality and morbidity, absenteeism, severe decreases in the quality of life, and reduced productivity.

    Obesity, which is currently estimated to have a prevalence of 30% in the USA, also has profound impacts on personal and social health. It reduces female fertility, promotes loss of cognitive ability, reduces the lifespan, and may increase employment difficulty.

    Conclusions

    Obesity and depression have common origins and act to exacerbate each other. This interrelationship significantly impacts the quality of life. One possible explanation for their connections may be via gut dysbiosis.

    This has stimulated much study on the potential use of probiotics and prebiotics in depression and anxiety, as well as in obesity.

    Encouraging findings from existing research underscore the need for robust clinical trials to evaluate the therapeutic potential of microbiota modulation.”

    [ad_2]

    Source link

  • Metabolic markers tied to increased risk of depression and anxiety, study finds

    Metabolic markers tied to increased risk of depression and anxiety, study finds

    [ad_1]

    In a recent study published in the JAMA Network Open, a group of researchers determined if carbohydrate, lipid, and apolipoprotein (Apo) biomarkers are linked to the future development of depression, anxiety, and stress-related disorders in a large Swedish cohort.

    Study: Metabolic Profile and Long-Term Risk of Depression, Anxiety, and Stress-Related Disorders. Image Credit: hikrcn / ShutterstockStudy: Metabolic Profile and Long-Term Risk of Depression, Anxiety, and Stress-Related Disorders. Image Credit: hikrcn / Shutterstock

    Background 

    About one-third of people experience depression, anxiety, and stress-related disorders in their lifetime, with growing evidence suggesting a link between these psychiatric conditions and metabolic dysregulation, such as lipid and glucose abnormalities that trigger inflammation. This inflammation may increase the risk of psychiatric disorders by affecting brain health. However, existing research on metabolic biomarkers and their association with psychiatric disorders has been inconsistent, often limited by methodological issues like short follow-up periods and reliance on self-reported depression measures, mainly in older adults. Furthermore, there is a notable gap in research on the connection between these biomarkers and anxiety or stress-related disorders, particularly the long-term effects of Apo’s. Further research is crucial to clarify these associations and explore potential preventative and therapeutic strategies.

    About the study 

    The Swedish Apolipoprotein-Related Mortality Risk (AMORIS) cohort, spanning from 1985 to 1996 and predominantly in the Stockholm region, includes 812,073 participants (49% men, 51% women) who underwent routine health screenings or were referred for laboratory testing due to health conditions. For this study, 211,200 participants over 16, free from mental disorders at baseline and with at least one biomarker measurement, were selected. Mental disorder histories were confirmed using the Swedish Patient Register, employing various International Classification of Diseases (ICD) revisions for accuracy.

    The study included a broad spectrum of stress-related conditions, with both primary and secondary diagnoses considered. Biomarkers of interest include glucose, cholesterol types, triglycerides, apolipoproteins, and their ratios, analyzed by consistent laboratory methods. Covariates like sex, age, fasting status, socioeconomic status, and birth country were also recorded, offering a detailed background for each participant.

    Statistical analysis involved Cox proportional hazards regression models to explore the relationship between initial biomarker levels and the risk of psychiatric disorders, adjusting for relevant covariates and employing both categorical and continuous variable analyses. Sensitivity analyses further refined these findings by focusing on employed individuals, outpatient referrals and excluding those with missing socioeconomic data. A case-control study embedded within the larger cohort provided a longitudinal perspective, examining biomarker trends up to 30 years before diagnosis, with controls matched to cases by sex, age, and enrollment year. 

    Study results 

    In the substantial cohort of 211,200 participants, consisting of 58% males and 42% females, with the vast majority born in Sweden (89.4%), the study observed notable trends over a mean (SD) follow-up period of 21 years. The participants had an average age of 42.1 years at their first blood sampling, with diagnoses of depression, anxiety, or stress-related disorders emerging at a mean age of 60.5 years. The incidence rates for these disorders varied, with depression, anxiety, and stress-related disorders recorded at rates of 21.5, 16.6, and 10.5 per 10,000 person-years, respectively. Notably, a segment of the cohort was diagnosed with multiple disorders, yet only 0.4% received diagnoses across all three categories.

    The analysis revealed a correlation between metabolic biomarker levels and psychiatric health risks. Elevated glucose and triglyceride (TG) levels significantly increased the risk of psychiatric disorders, whereas higher levels of high-density lipoprotein cholesterol (HDL-C) offered a protective effect. The delineation of risk did not change markedly between low and normal glucose levels, suggesting a particular risk threshold. This pattern persisted across gender lines and when evaluating each psychiatric condition individually, reinforcing the robustness of these findings.

    Further analysis, specifically among employed individuals, yielded consistent results with the primary analysis, underscoring the relationship between metabolic health and psychiatric conditions regardless of employment status. When examining the impact of outpatient care referrals on biomarker measurements, the associations remained similar for glucose and TGs, though the protective role of HDL-C lessened. Additionally, higher levels of low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), ApoB, and the ApoB/ApoA-I ratio were inversely associated with the risk of psychiatric disorders, indicating a complex interplay between various lipid biomarkers and mental health.

    Socioeconomic status also emerged as a significant factor, with lower incidence rates of psychiatric disorders observed among those with higher socioeconomic standing. This trend held true even after adjusting for potential confounders, including missing socioeconomic data, further emphasizing the socioeconomic gradient in psychiatric disorder risk.

    Longitudinal analysis, tracking biomarker levels up to 30 years prior to diagnosis, illustrated that patients eventually diagnosed with anxiety, depression, or stress-related disorders exhibited consistently higher levels of TGs, glucose, and TC two decades before diagnosis. Additionally, higher levels of ApoA-I and ApoB were noted in the decade leading up to diagnosis, indicating a prolonged period of metabolic dysregulation preceding psychiatric diagnoses. 

    [ad_2]

    Source link

  • New treatments in sight for challenging neuropsychiatric symptoms in neurodegenerative diseases

    New treatments in sight for challenging neuropsychiatric symptoms in neurodegenerative diseases

    [ad_1]

    In a recent study published in the journal JAMA Neurology, researchers reviewed the progress thus far in pharmacologically managing the various neuropsychiatric syndromes that manifest in neurodegenerative disorders and discussed the recent advances in understanding the pathobiology of neurodegenerative disorders that help improve clinical care and therapy.

    Study: Progress in Pharmacologic Management of Neuropsychiatric Syndromes in Neurodegenerative Disorders. Image Credit: PopTika / ShutterstockStudy: Progress in Pharmacologic Management of Neuropsychiatric Syndromes in Neurodegenerative Disorders. Image Credit: PopTika / Shutterstock

    Neurodegenerative disorders and neuropsychiatric syndromes

    Neurodegenerative disorders encompass a wide range of conditions, many of which are a factor of progressing age and manifest symptoms only in late middle age or old age. However, with the growing aging population in the world, the frequency of neurodegenerative disorders and associated conditions continues to increase. While Lewy body dementia, Parkinson’s disease, Huntington’s disease, and Alzheimer’s disease are some of the more commonly heard neurodegenerative disorders, others include frontotemporal dementia, corticobasal syndrome, progressive supranuclear palsy, amyotrophic lateral sclerosis, chronic traumatic encephalopathy, traumatic encephalopathy syndrome, and multiple system atrophy.

    All neurodegenerative disorders are associated with neuropsychiatric syndromes, with neuropsychiatric syndromes being part of the diagnostic criteria for some of the neurodegenerative disorders. These neuropsychiatric syndromes can occur sequentially or simultaneously and play a major role in functional impairment and overall decline in quality of life, not to mention adding to caregiver distress.

    Non-pharmacological interventions such as psychosocial treatments have been extensively explored to ameliorate neuropsychiatric syndromes in cases of neurodegenerative disorders and to prevent relapse. These include exercise programs, environmental modifications, music, acupressure and massage therapy, activities such as art in combination with music, and animal-assisted interventions.

    However, in cases where psychosocial interventions are not successful in reducing the symptoms of neuropsychiatric syndromes or in cases where the patient might be a threat to themselves or others, pharmacological interventions are preferred. Although the development of pharmacological therapies to treat neuropsychiatric syndromes has been challenging, several medications have been approved for use by the United States (U.S.) Food and Drug Administration (FDA), specifically for patients with neurodegenerative disorders.

    In the present review, the researchers discussed in detail five of the major neuropsychiatric syndromes, their occurrence, symptoms, and options for pharmacological management of these syndromes.

    Depression

    Depression is one of the common symptoms of neurodegenerative disorders, with a high prevalence of major depressive disorders among patients with dementia. In patients with Alzheimer’s disease dementia, depression that is not diagnosed or treated in time often accelerates cognitive decline, suicide risk, and mortality risk. The incidence of depression in other neurodegenerative disorders such as Parkinson’s disease, multiple system atrophy, and dementia with Lewy bodies can often be close to 80%.

    Although the diagnosis of depression in patients with neurodegenerative disorders is challenging, selective serotonin reuptake inhibitors and selective serotonergic and noradrenergic reuptake inhibitors have been prescribed. For depression that is life-threatening or psychotic, electroconvulsive therapy has often been effective. However, studies have found that Alzheimer’s disease pathology involving a high brain amyloid burden can result in resistance to pharmacotherapy.

    Disinhibition

    Disinhibition has often been observed in patients with progressive supranuclear palsy, Huntington’s disease, and Alzheimer’s disease. It involves behavior that is considered inappropriate according to social norms, such as touching strangers, making sexually explicit jokes or remarks, improper sexual acts, speaking loudly, and oversharing personal details. It is most common in patients with the behavioral variant of frontotemporal dementia.

    Atypical antipsychotics, selective serotonin reuptake inhibitors, and antiepileptic or mood-stabilizing agents have often been used to treat disinhibition. However, none of these are specifically for treating disinhibition in patients with neurodegenerative disorders.

    Apathy

    Apathy in dementia patients is often linked to a two-fold increase in the risk of cognitive decline. It is believed to increase caregiver distress, decrease treatment responses, and elevate the risk of frailty. While no approved treatments exist for apathy in patients with neurodegenerative disorders, psychosocial interventions, noninvasive brain stimulation, and non-psychostimulant pharmacologic interventions have been explored.

    Psychosis

    Psychosis, which involves a wide range of delusions and hallucinations, has varied associations with different neurodegenerative disorders. Patients with dementia with Lewy bodies often experience misidentification, misrepresentation, visual hallucinations, and feelings of presence, while frontotemporal dementia patients often also experience paranoia. The antipsychotics that have been approved for patients with neurodegenerative disorders based on results from placebo-controlled, double-blind trials include Pimavanserin, Risperidone, and Aripiprazole.

    Agitation

    One of the most prevalent and disruptive neuropsychiatric syndromes in most neurodegenerative disorders is agitation, which involves kicking, shoving, shouting, hitting, and resisting care. It is associated with rapid progression of dementia and earlier mortality. Agitation also results in a higher probability of hospitalization and substantially negatively impacts the quality of life of the patients and their families.

    Agitation is often treated with antipsychotics such as Risperidone, Aripiprazole, Quetiapine, and Brexpiprazole. Antidepressants such as Citalopram and the anticonvulsant Carbamazepine have also been used as pharmacological treatment options for agitation.

    Conclusions

    To summarize, the review examined the latest advances in the pharmacological management of neuropsychiatric syndromes associated with neurodegenerative disorders. The researchers provided a comprehensive summary of the symptoms of five major neuropsychiatric syndromes and the pharmacological options for their management.

    [ad_2]

    Source link

  • For-profit companies open psychiatric hospitals in areas clamoring for care

    For-profit companies open psychiatric hospitals in areas clamoring for care

    [ad_1]

    A for-profit company has proposed turning a boarded-up former nursing home here into a psychiatric hospital, joining a national trend toward having such hospitals owned by investors instead of by state governments or nonprofit health systems.

    The companies see a business opportunity in the shortage of inpatient beds for people with severe mental illness.

    The scarcity of inpatient psychiatric care is evident nationwide, especially in rural areas. People in crisis often are held for days or weeks in emergency rooms or jails, then transported far from their hometowns when a bed opens in a distant hospital.

    Eight nonprofit Iowa hospitals have shuttered their psychiatric units since 2007, often citing staffing and financial challenges. Iowa closed two of its four mental health institutions in 2015.

    The state now ranks last in the nation for access to state-run psychiatric hospitals, according to the Treatment Advocacy Center. The national group, which promotes improving care for people with severe mental illness, recommends states have at least 50 state-run psychiatric beds per 100,000 people. Iowa has just two such beds per 100,000 residents, the group said.

    Two out-of-state companies have developed psychiatric hospitals in Iowa in the past four years, and now a third company has obtained a state “certificate of need” to open a 60-bed facility in Grinnell.

    Before 2020, Iowa had no privately owned, free-standing psychiatric hospitals. But several national companies specialize in developing such facilities, which treat people in crisis from conditions such as depression, schizophrenia, or bipolar disorder, sometimes compounded by drug or alcohol abuse. One of the companies operating in Iowa, Universal Health Services, says it has mental health facilities in 39 states.

    Lisa Dailey, the Treatment Advocacy Center’s executive director, said that for-profit hospitals don’t necessarily provide worse care than nonprofit ones but that they tend to be less transparent and more motivated by money. “Private facilities are private,” she said. “As a result, you may not have a great insight into why they make the decisions that they make.”

    Dailey said solid data on privately run mental health hospitals nationwide is scarce. But she has heard for-profit companies have recently set up free-standing psychiatric hospitals in several states, including California. The California Department of Public Health confirmed three such facilities have opened there since 2021, in Aliso Viejo, Madera, and Sacramento.

    The latest Iowa psychiatric hospital would be housed in a vacant nursing home on the outskirts of Grinnell, a college town of 9,500 people in a rural region of the state. The project’s developers noted there are no other inpatient mental health facilities in Poweshiek County, where Grinnell is located, or in any of the eight surrounding counties. The nearest inpatient mental health facilities are 55 miles west in Des Moines.

    The Indiana-based company proposing the hospital, Hickory Recovery Network, primarily runs addiction treatment centers in Indiana. But it opened psychiatric hospitals in Ohio and Texas in 2023 and 2024, and it told Iowa regulators it could open the Grinnell hospital by August.

    An affiliated company ran the facility as a nursing home, called the Grinnell Health Care Center, until 2022, according to a Hickory Recovery Network filing with Iowa regulators.

    Medicare rated the nursing home’s overall quality at just two out of five stars. And in 2020, the facility was suspended indefinitely from Iowa’s Medicaid program because of billing issues, state records show.

    Officials from Hickory Recovery Network responded only briefly to KFF Health News inquiries, including about how the former Iowa nursing home’s spotty record could affect the proposed psychiatric hospital.

    In a short telephone interview in February, Melissa Durkin, the company’s chief operating officer, declined to say who owns Hickory Recovery Network.

    Durkin denied in the interview that her organization was associated with the company that ran the defunct and troubled Grinnell nursing home.

    However, Hickory Recovery’s application for a certificate of need refers to the nursing home operator as “Hickory’s affiliated company.” In testimony before Iowa regulators, Durkin made a similar reference as she expressed confidence her organization could find sufficient staff to reopen the facility as a psychiatric hospital. “We have a history with that building. We operated a nursing home there before,” she said at the video-recorded hearing.

    Durkin said in the interview that company leaders had not decided for sure to redevelop the vacant Iowa nursing home into a psychiatric hospital, although they twice went through the complicated process of applying for a state “certificate of need” for the project. The first attempt was stymied in 2023 by a tie vote of the board that considers such permits, which are a major hurdle for large health care projects. The second application was approved by a unanimous vote after a hearing on Jan. 25.

    Keri Lyn Powers, a Hickory executive, told regulators the company planned to spend $1.5 million to remodel the building. The main changes would include making rooms safe for people who might be suicidal, she said.

    The company predicted in its application that 90% of the hospital’s patient revenues would come from Medicare or Medicaid, public programs for seniors or people who have low incomes or disabilities. It doesn’t mention that the nursing home was suspended from Iowa’s Medicaid program, which covers about half of the state’s nursing home residents.

    Iowa authorities suspended the Grinnell Health Care Center nursing home in 2020 for failing to repay nearly $25,000 in overpayments from Medicaid, state records show. When the nursing home closed in 2022, its former medical director told the local newspaper part of the reason for its demise was its inability to collect Medicaid reimbursements. Iowa administrators recently notified the owners that the former nursing home owed $284,676 to Medicaid. A state spokesperson said in March that neither amount had been repaid.

    The proposal to reopen the building as a psychiatric hospital won support from patient advocates, Grinnell’s nonprofit community hospital, and the regional mental health coordinator.

    The only opposition at the state hearing came from Kevin Pettit, leader of one of Iowa’s two other private free-standing psychiatric hospitals. Pettit is chief executive officer of Clive Behavioral Health Hospital, a 100-bed facility in suburban Des Moines that opened in 2021. Pettit told regulators he supports expanding mental health services, but he predicted the proposed Grinnell facility would struggle to hire qualified employees.

    He said despite strong demand for care, many Iowa psychiatric facilities are limiting admissions. “The beds exist, but they’re not actually open, … because we’re dealing with staffing issues throughout the state,” Pettit testified.

    Overall, Iowa has 901 licensed inpatient mental health beds, including in psychiatric units at community hospitals, in free-standing psychiatric hospitals, and in the two remaining state mental health institutes, according to the Iowa Department of Health and Human Services. But as of January, just 738 of those beds were staffed and being used.

    Pettit’s facility is run by Pennsylvania-based Universal Health Services in partnership with MercyOne, a hospital system based in the Des Moines area.

    In an interview, Pettit said his hospital only has enough staff to use about half of its beds. He said it’s especially difficult to recruit nurses and therapists, even in an urban area with a relatively robust labor supply.

    State inspectors have cited problems at the Clive facility, including four times declaring that deficiencies put patients’ safety in “immediate jeopardy.” Those issues included insufficient staff to properly monitor patients and insufficient safeguards to prevent access to items patients could use to choke or cut themselves.

    Pettit said such citations are not unusual in the tightly regulated industry. He said the organization is committed to patient safety. “We value the review by our regulatory entities during the survey process and view any finding as an opportunity for continuous improvement of our operations,” he wrote in an email.

    Iowa’s other privately owned psychiatric hospital, Eagle View Behavioral Health in Bettendorf, also has been cited by state inspectors. The 72-bed hospital was purchased in 2022 by Summit BHC from Strategic Behavioral Health, which opened the facility in 2020. Both companies are based in Tennessee.

    State inspectors have cited the Bettendorf facility twice for issues posing “immediate jeopardy” to patient safety. In 2023, inspectors cited the facility for insufficient supervision of patients, “resulting in inappropriate sexual activity” between adult and adolescent patients. In 2021, the facility was cited for insufficient safety checks to prevent suicide attempts and sexual misconduct.

    Eagle View officials did not respond to requests for comment.

    Advocates for Iowa patients have supported the development of free-standing psychiatric hospitals.

    Leslie Carpenter of Iowa City, whose adult son has been hospitalized repeatedly for severe mental illness, spoke in favor of the Grinnell facility’s application for a certificate of need.

    In an interview afterward, Carpenter said she was optimistic the new facility could find enough staff to help address Iowa’s critical shortage of inpatient psychiatric care.

    She said she would keep a close eye on how the new facility fares. “I think if a company were willing to come in and do the job well, it could be a game changer.”




    Kaiser Health NewsThis article was reprinted from khn.org, a national newsroom that produces in-depth journalism about health issues and is one of the core operating programs at KFF – the independent source for health policy research, polling, and journalism.

    [ad_2]

    Source link

  • Green environments linked to lower depression and anxiety risk, study finds

    Green environments linked to lower depression and anxiety risk, study finds

    [ad_1]

    In a prospective cohort study published in the journal Nature Mental Health, researchers in China investigated the potential association between exposure to residential greenness and the incidence of anxiety and depression and explored the underlying pathways. They found prolonged residence in green environments was linked to a lower risk of depression and anxiety, potentially via air pollution.

    Study: Long-term exposure to residential greenness and decreased risk of depression and anxiety. Image Credit: p-jitti / ShutterstockStudy: Long-term exposure to residential greenness and decreased risk of depression and anxiety. Image Credit: p-jitti / Shutterstock

    Background

    Mental disorders, including depression and anxiety, are among the most debilitating conditions, with their impact on global health burden rising steadily. These disorders affect millions worldwide and are influenced by genetic, behavioral, and environmental factors. Recognizing modifiable factors associated with mental health issues could offer valuable targets for interventions and inform potential treatment strategies.

    A growing body of evidence now recognizes residential greenness as a significant environmental factor in reducing stress and improving health, particularly mental well-being. While some longitudinal studies suggest a negative association between green spaces and depression, inconsistent findings highlight the need for larger, well-designed prospective cohort studies to better understand this relationship. Although long-term exposure to greenness is hypothesized to provide cumulative mental health benefits through various pathways, there is a dearth of population-based evidence, and the predominant mechanism remains uncertain. In the present cohort study, researchers explored the link between long-term exposure to residential greenness, depression, and anxiety while examining the potential pathways and factors.

    About the study

    Data from 409,556 participants were obtained from the United Kingdom (UK) Biobank, a large prospective cohort. The median age of participants was 58 years, and 52.4% were female. About 90.8% of the participants were white, and 86.2% resided in urban areas. Participants provided detailed information through questionnaires, physical measurements, and biological samples. The analysis focused on associations between residential greenness and incident depression and anxiety, excluding those with pre-existing mental health issues. Subsets of participants were analyzed to explore the potential pathways. The mean follow-up duration was 11.9 years.

    Greenness around residential areas was evaluated using NDVI (short for Normalized Difference Vegetation Index), a measure based on land surface reflection of infrared wavelengths within buffer regions of sizes 300 m, 500 m, 1,000 m, and 1,500 m. Data were obtained from moderate-resolution imaging spectroradiometer remote sensing. Preprocessing was performed to remove cloudy and snow-covered areas, and water body impacts were addressed. Anxiety or depression diagnoses at baseline and follow-up were confirmed using hospital admissions, death registry, primary care records, and self-reports verified by healthcare professionals. Cases were identified using the International Statistical Classification of Diseases and Related Health Problems (ICD-10) codes.

    Various potential confounders and mediators were considered in the analysis, including sociodemographic factors (age, gender, ethnicity, income, education, residence location), lifestyle factors (body mass index (BMI), smoking status, drinking status), and environmental factors (air pollutants, noise, water percentage, urban morphometric measures). Statistical analyses involved time-varying Cox proportional hazard models, hazard ratios (HR), restricted cubic splines, mediation analysis, subgroup analysis, and sensitivity analysis.

    Results and discussion

    In the study period, about 4.1% and 3.5% of the total participants were diagnosed with anxiety (HR = HR = 0.86) and depression (HR = 0.84), respectively. Residential greenness exposure consistently showed a protective effect on depression and anxiety, with significant reductions in risk observed across different buffer sizes. Mediation analyses indicated that air pollution, mainly particulate matter of diameter 2.5 microns (PM2.5), NO2, NOx, SO2, and O3, significantly mediated the associations between NDVI and both depression and anxiety. Further, IMD (short for index of multiple deprivation) was found to mediate the association between NDVI and depression. Additionally, factors such as distance to coast, factory, and healthcare places, as well as lifestyle factors like sleep duration and social engagement, showed small but significant mediation effects. The protective effects of green surroundings were found to be more pronounced against depression and anxiety in older adults and males.

    Sensitivity analyses confirmed the robustness of the main findings. The large sample size, long follow-up duration, detailed adjustment for potential confounders, and exploration of potential mediators strengthen the findings. However, the study is limited by the lack of details on green space quality, the potential influence of extraneous factors on greenness exposure, healthy volunteer bias, and potential bias introduced by using diagnosis rather than symptom onset. Further research is warranted to confirm these findings.

    Conclusion

    In conclusion, this is the first prospective cohort study to provide comprehensive insights into the association between exposure to greenness and mental health. The findings reveal that long-term exposure to residential greenness is linked to lower risks of depression and anxiety. Higher levels of green surroundings showed more substantial positive effects on mental health, with reduced air pollution identified as a significant mediator. These findings call for strategic urban planning interventions by local governments to promote mental well-being by enhancing green spaces.

    [ad_2]

    Source link

  • Promising new compound reduces alcohol dependence in animal studies

    Promising new compound reduces alcohol dependence in animal studies

    [ad_1]

    Scripps Research scientists have found that LY2444296-;a compound that selectively blocks the kappa opioid receptor (KOP)-;may reduce drinking in cases of alcohol dependence in animal studies. The findings, which were published March 9, 2024, in Scientific Reports, could eventually inform new treatment options for people who experience alcohol use disorder (AUD).

    Compounds designed to selectively block the KOP are very promising because this receptor is involved in a lot of mental illnesses, such as anxiety and depression. The KOP system is also important in alcohol use disorder, so the idea is if it’s targeted and blocked, you can stop alcohol abuse.”


    Rémi Martin-Fardon, PhD, Associate Professor, Department of Molecular Medicine

    The KOP system controls brain circuits that affect a range of neurological processes, including addiction, emotion, pain and reward seeking. Both acute and chronic exposure to alcohol negatively affects this system, according to the study’s first author, Francisco Flores-Ramirez, PhD, a postdoctoral fellow at Scripps Research.

    For their study, Martin-Fardon and Flores-Ramirez sought to find out whether orally administering LY2444296 could decrease alcohol consumption in rats that formed alcohol dependency. The aim was to mitigate withdrawal symptoms, which would hypothetically lead to reduced alcohol intake. Once rats received LY2444296 at doses as low as 3 mg per kg following 8 hours of abstinence-;when acute withdrawal symptoms typically start-; withdrawal signs and alcohol consumption tapered down significantly. The researchers also determined that LY2444296 may be innocuous, as it had neither a positive nor negative effect on rats without alcohol dependency.

    Martin-Fardon and his team didn’t expect LY2444296 to reduce withdrawal signs after only 8 hours of alcohol abstinence because earlier studies showed that other compounds capable of binding to the KOP had no effect on alcohol withdrawal. The scientists don’t yet know why LY2444296 was effective in the present study, and they plan to investigate further.

    “People drink to get rid of the sensations of withdrawal,” Martin-Fardon says. He added that withdrawal is associated with physical pain, and that oftentimes, “the only thing that can fix the problem is to have a drink.” But if LY2444296 is taken before withdrawal symptoms begin, “you can decrease the symptoms, so you feel better and drink less.”

    Still, the question remains which specific parts of the brain are best targeted to mitigate withdrawal symptoms. Next on their agenda, Martin-Fardon and Flores-Ramirez hope to determine whether LY24444296 can block the effects of stress and other cues that can trigger alcohol relapse.

    “We’re also interested in what brain regions are changing as a function of alcohol dependence,” Flores-Ramirez says. “Maybe we could target them to see if the compound could reverse both drinking and relapse behavior.”

    Source:

    Journal reference:

    Flores-Ramirez, F. J., et al. (2024). LY2444296, a κ-opioid receptor antagonist, selectively reduces alcohol drinking in male and female Wistar rats with a history of alcohol dependence. Scientific Reports. doi.org/10.1038/s41598-024-56500-9.

    [ad_2]

    Source link

  • Study reveals strong bidirectional relationship between perinatal depression and premenstrual disorders

    Study reveals strong bidirectional relationship between perinatal depression and premenstrual disorders

    [ad_1]

    Women affected by premenstrual disorders have a higher risk of perinatal depression compared with those who do not, according to research published March 28th in the open access journal PLOS Medicine. The relationship works both ways: those with perinatal depression are also more likely to develop premenstrual disorders after pregnancy and childbirth. This study suggests that a common mechanism might contribute to the two conditions.

    Menstruating women experience cyclical hormone fluctuations through puberty, menstrual cycle, pregnancy and menopause. Some women have difficult to manage symptoms of low mood and depression during these fluctuations. Between a fifth and a third of women are reportedly affected by premenstrual disorders and 11% of mothers suffer perinatal depression -; depressive symptoms during pregnancy and up to 12 months after delivery.

    Qian Yang and colleagues at the Karolinska Institutet, Sweden and University of Iceland used the Swedish nationwide registers from 2001 to 2018 and identified 84,949 women with perinatal depression and 849,482 unaffected women. The researchers matched the women on age and calendar year, and further controlled for demographic factors, smoking, BMI, parity and history of psychiatric disorders. Among women with perinatal depression, almost 3% had premenstrual disorders before pregnancy compared with 0.6% of matched unaffected women. Women with perinatal depression were also twice as likely to report premenstrual disorders when the menstruation resumed after childbirth, compared to those unaffected by perinatal depression.

    The research sheds light on the association between the two conditions and supports a theory that they may share underlying biological mechanisms and/or risk factors. Understanding this association could help healthcare providers to better target support to women most likely to be affected.

    The authors add, “This study reveals a strong bidirectional relationship between perinatal depression and premenstrual disorders, using data from over 900,000 pregnancies. The findings suggest that both disorders may exist on a continuum, and emphasize the importance of recognizing these susceptibilities in clinical practice.

    Source:

    Journal reference:

    Yang, Q., et al. (2024) The bidirectional association between premenstrual disorders and perinatal depression: A nationwide register-based study from Sweden. PLOS Medicine. doi.org/10.1371/journal.pmed.1004363.

    [ad_2]

    Source link

  • Having a ruff day? Study says spending time with dogs can help

    Having a ruff day? Study says spending time with dogs can help

    [ad_1]

    In a recent study published in PLoS ONE, researchers examined how interacting with dogs affects the emotions and psychophysiology of humans using an electroencephalogram (EEG).

    Their results indicate that people are significantly less stressed when they interact with dogs, with specific activities showing associations with heightened emotional stability, relaxation, creativity, concentration, and attention.

    Study: Psychophysiological and emotional effects of human–Dog interactions by activity type: An electroencephalogram study. Image Credit: 4 PM production/Shutterstock.comStudy: Psychophysiological and emotional effects of human–Dog interactions by activity type: An electroencephalogram study. Image Credit: 4 PM production/Shutterstock.com

    Background

    Since the domestication of dogs more than 30,000 years ago, they have been humans’ constant companions, providing invaluable assistance for herding livestock, guarding people and property, hunting, and working in many other domains.

    The emotional and physiological benefits of interacting with animals, particularly dogs, are now well-known, as they reduce levels of cortisol and, thus, behavioral distress, anxiety, and stress reactivity and improve mental and cardiovascular health.

    This has led to the use of animal-assisted interventions (AAI) and animal-assisted activities (AAA) for various domains such as social work, education, and health.

    However, the effects of these interventions have usually been assessed using before-after or experiment-control comparisons, and evidence on the underlying mechanisms, such as changes in brain activity, is lacking.

    About the study

    In this study, researchers investigated people’s psychophysiological responses while interacting with dogs through various activities.

    Participants were recruited from an animal grooming academy and pet salons in South Korea, excluding those with cynophobia or dog allergies and a medical history of conditions like unstable angina, high blood pressure, heart surgery, heart attack, or psychopathological disease.

    Individuals receiving medication for these conditions or pregnant or lactating were also excluded. During the study, participants avoided stimulants and did not drink caffeinated beverages or smoke.

    The dog they interacted with was a four-year-old female poodle who had been trained in aggression, sociability, manners, and basic obedience. She was healthy and vaccinated, and a professional handler was available to ensure her safety.

    Participants engaged in eight activities in a single session: meeting, walking, hugging, photography, grooming, massage, feeding, and play. These activities were chosen to prioritize direct interactions and take place over an hour.

    Their responses were measured using EEGs for three minutes during each activity, while their emotional responses were assessed using self-reported mood questionnaires such as the Stress Numeric Rating Scale (Stress NRS), the Profile of Mood State (POMS), and the Semantic Differential Method (SDM). Demographic information like weight, height, sex, and age were also collected.

    The collected data were analyzed using descriptive statistics, one-way analysis of variance (ANOVA), statistical testing, and Duncan’s post-hoc analysis.

    Findings

    The study included 30 individuals, of whom 15 were male and 15 were female, and they were 27.9 years old on average.

    Results from the EEG analysis showed that playing with the dog significantly increased activity in both frontal lobes and the left prefrontal lobe.

    Walking also boosted activity in both prefrontal lobes. Playing correlated with heightened activation in both frontal lobes, while walking specifically activated the right prefrontal lobe.

    Massage and grooming activities are elevated in the prefrontal and left frontal lobes. Massage also activated the right frontal lobe. However, no significant differences were found across activities in the parietal and occipital lobes.

    Playing with the dog showed consistent activation in multiple brain regions, including those associated with focused attention, meditative states, and cognitive and sensory processing areas.

    The subjective reports of emotional states were analyzed across six categories, namely depression-dejection, fatigue, tension-anxiety, confusion, vigor, and anger-hostility.

    Individuals reported lower levels of depression, fatigue, and stress during AAAs than they did while resting. They also experienced more vigor when they engaged in feeding, relaxed when they engaged in massaging the dog, and comfortable when they walked her.

    Participants experienced more positive mood states when they hugged, massaged, or fed her.

    Conclusions

    The findings from this study, which included both pet owners and those without pets, support the use of AAI for stress management and emotional relaxation, with different activities eliciting different brainwave reactions.

    Responses in the prefrontal lobe are significant as this region plays important roles in regulating memory, language, emotional, behavioral, and cognitive functioning while the parietal lobe is essential for perceiving stimuli, motor function control, spatial orientation comprehension, and sensory information integration.

    In addition to the limited sample size, another possible limitation of this study is that participants in AAI are more likely to be those who are not afraid of animals and enjoy being with them.

    People without a pre-existing fondness for animals are likely to respond very differently to AAA, and this difference could lead to a selection bias in the findings.

    Further studies are needed to validate these findings and shed more light on the mechanisms that make interacting with dogs and other animals so beneficial for humans.

    [ad_2]

    Source link